Yardstick Research tear-sheet / pharma & life sciences CRM cohort

Methodology · how we score · rubric weights in plain sight · vendors received this sheet seven days before publication and could flag factual errors, never rankings

ZS ZAIDYN

Identity

• Founded: ZS founded 1983 (by Andris Zoltners and Prabhakant Sinha, Northwestern University); ZAIDYN platform launched June 2023. [VENDOR-CLAIMED - https://www.zs.com/about]
• HQ: Evanston, Illinois (global headquarters; operating hubs in Chicago, Princeton, New York, London, Pune, Bangalore) [VENDOR-CLAIMED - https://www.zs.com/about]
• Legal entity: ZS Associates, Inc. (private; not publicly traded) [VENDOR-CLAIMED - https://www.zs.com/about]
• Funding: Private; no disclosed funding rounds. Revenue not publicly reported. [UNKNOWN]
• Headcount: 15,000+ employees across 40+ offices worldwide. [VENDOR-CLAIMED - https://www.zs.com/about]
• Recent news (last 12 months):
• 2025 - ZS ranked as the highest-rated Leader in the 2025 Everest Group Life Sciences AI and Analytics Services PEAK Matrix. [THIRD-PARTY - https://www.zs.com/]
• 2025 - Forbes named ZS to its 2025 America's Best Management Consulting Firms list. [THIRD-PARTY - https://www.zs.com/]
• 2025 - EcoVadis placed ZS in the top 5% globally for sustainability performance. [THIRD-PARTY - https://www.zs.com/]
• 2025 - ZS expanded ZAIDYN's agentic AI capabilities with new commercial intelligence modules targeting pharma field force optimization. [VENDOR-CLAIMED - https://www.zs.com/]
• 2024 - ZS case studies with Amgen and Gilead published on commercial analytics and field force optimization use cases. [VENDOR-CLAIMED - https://www.zs.com/about]
• Archetype: AI-native commercial intelligence platform purpose-built for life sciences. ZAIDYN bundles next-best-action (NBA) engine, omnichannel orchestration, field force analytics, and HCP engagement scoring into a single platform that sits above - and connects into - existing CRMs (Veeva Vault CRM, Salesforce Health Cloud, IQVIA OCE). It is the technology productization of ZS Associates' 40-year body of pharma commercial analytics consulting work. Primary buyers are VP Commercial Analytics, Chief Commercial Officer, and Commercial Operations teams at mid-to-large pharma and biotech companies.

Total score: 80 / 100

• Stage fit:
• Foundation (<40 readiness): no - Requires mature commercial infrastructure (CRM, field force, data warehouse) to integrate with; not a standalone starting point.
• Pilot (40-59): conditional - Possible for companies with an existing ZS consulting relationship that can extend into a ZAIDYN proof-of-concept, but standalone new-logo pilots are complex.
• Scale (60-79): yes - Strong fit for companies with established commercial operations building AI-driven HCP engagement at scale.
• Optimization (80+): yes - Strongest fit. Named customers (Amgen, Gilead) are at the Optimization stage; the platform's value compounds as historical engagement data accumulates in the NBA engine.
• One-line verdict: The most AI-capable commercial intelligence platform in the cohort for top-tier pharma field force optimization - highest AI depth score reflects genuine NBA engine maturity, with implementation complexity and compliance documentation gaps (21 CFR Part 11 not explicitly certified) as the primary risk factors.

Headline numbers

Dimension scores

Pricing detail

ZS does not publish pricing for ZAIDYN on any public surface. [UNKNOWN]

Key structural notes: - Consulting+software model. ZAIDYN is typically sold alongside ZS Analytics and consulting services. Buyers purchasing ZAIDYN without a ZS consulting relationship are rare; the platform's NBA engine performs best when calibrated by ZS consultants using the firm's proprietary pharma benchmarking datasets. - No self-serve or trial tier. Enterprise sales-led only. - Implementation services are material. CRM integration, data ingestion pipeline setup, and NBA model calibration are time- and cost-intensive; ZS typically delivers these via its commercial analytics practice. - Total cost of ownership: Higher than pure-SaaS CRM alternatives due to the consulting layer; lower than the equivalent outcome if attempted with generic BI tooling and a separate NBA vendor.

Integrations

Source: D1 integrates_with column; https://www.zs.com/

The integrates_with column for this vendor in D1 lists: veeva-vault-crm, salesforce-health-cloud, iqvia-oce.

• Veeva Vault CRM: ZAIDYN integrates with Veeva Vault CRM (the dominant CRM in US and global pharma commercial operations) to deliver NBA recommendations and engagement scoring to field reps and their managers. Integration depth - read-only analytics overlay vs. bidirectional action write-back - is not publicly documented. [VENDOR-CLAIMED - https://www.zs.com/]
• Salesforce Health Cloud: ZAIDYN supports Salesforce Health Cloud as an alternative CRM integration point for pharma companies running on the Salesforce commercial platform. [VENDOR-CLAIMED - https://www.zs.com/]
• IQVIA OCE: ZAIDYN integrates with IQVIA Orchestrated Customer Engagement (OCE), the third major CRM platform in pharma, covering companies that run on the IQVIA commercial stack. [VENDOR-CLAIMED - https://www.zs.com/]

Editorial assessment

ZS ZAIDYN occupies a distinct position in the pharma CRM and commercial intelligence market: it is not a CRM, it is an intelligence layer that sits above the CRM and tells it what to do. The next-best-action engine is the product's core differentiation, and the case for its accuracy rests on a genuine competitive moat - 40 years of ZS consulting work calibrating sales force sizing, territory design, HCP segmentation, and engagement frequency models for the pharma industry have generated proprietary benchmarking datasets that a pure-SaaS startup cannot replicate from scratch. The Everest Group 2025 PEAK Matrix recognition as the highest-rated Leader in Life Sciences AI and Analytics Services is a meaningful signal: Everest evaluates both capability and market impact, and that placement reflects ZAIDYN's position at the top of an increasingly competitive field.

The structural weaknesses are compliance documentation, integration depth transparency, and the consulting dependency. On compliance: ZAIDYN's public trust posture is effectively blank - no SOC 2 report, no ISO 27001 certificate, no 21 CFR Part 11 statement surfaces on zs.com as of research date. This is not necessarily evidence of non-compliance (ZS operates inside top-20 pharma clients with rigorous vendor qualification processes), but it is a procurement friction point for any buyer whose legal or security team requires documented certifications before contract. On integration: ZAIDYN's CRM connector list (Veeva, Salesforce, IQVIA OCE) is the right list, but the public description of what those integrations actually do - whether they write NBA recommendations back into CRM activity records, or simply surface them in a parallel dashboard - is not documented on a public surface. On consulting dependency: ZAIDYN's most defensible use cases require ZS consultants to calibrate the NBA engine; buyers evaluating ZAIDYN as a standalone SaaS tool without an accompanying ZS engagement are evaluating a different product than the reference cases suggest.

The right buyer for ZAIDYN is a commercial operations leader at a $250M+ pharma company who already has a ZS relationship, has established CRM infrastructure (Veeva, Salesforce, or IQVIA OCE), and needs AI-driven HCP prioritization and omnichannel orchestration at field force scale. The wrong buyer is a mid-market specialty pharma team looking for a fast-to-deploy commercial analytics layer with published pricing and a documented compliance posture.

Cohort context: In the pharma-lifesci-crm cohort, ZAIDYN sits at a distinct layer from Veeva Vault (content lifecycle management), Komodo Health (real-world data), and EVERSANA/Indegene (commercial outsourcing). ZAIDYN's primary competition for commercial analytics and NBA at top-tier pharma is IQVIA OCE and Salesforce's own Einstein AI layer. The cohort score of 80 reflects top-tier AI depth and vertical specialization offset by the compliance documentation gap and implementation complexity that characterize the product.

Best for

• Stage: Scale (60-79) and Optimization (80+). Conditional Pilot if existing ZS consulting relationship is in place.
• Company profile: $250M+ revenue pharma or large biotech with established commercial operations, existing CRM infrastructure (Veeva, Salesforce, or IQVIA OCE), and VP-level or above commercial analytics leadership.
• Industry fit: Strong for branded pharma (oncology, specialty, primary care), large biotech with commercial-stage products, global pharma with multi-market field force. Moderate for medical devices (different regulatory and commercial dynamics). Not a fit for pre-commercial biotech or pharma companies without a field force.
• Sales motion: Typically bundled with ZS commercial analytics consulting engagement; pure platform procurement is uncommon. Multi-quarter enterprise sales cycle.
• Annual tooling budget: $1M+ per year estimated (platform + consulting); exact range not publicly disclosed. [UNKNOWN]
• Skip if: (a) Documented SOC 2 / ISO 27001 / 21 CFR Part 11 compliance is required before contract (not surfaced publicly); (b) Fast time-to-value (under 6 months) is a procurement criterion; (c) No existing CRM infrastructure to connect ZAIDYN to; (d) Budget does not accommodate a consulting-layer engagement alongside software licensing; (e) Transparent published pricing is required before procurement can start.

Right-of-reply

ZS received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. ZS was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. ZS was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.

Right-of-reply gaps

Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:

1. SOC 2 Type II. No public SOC 2 report, ISO 27001 certificate, or trust center page was found on zs.com as of research date. Does ZS hold SOC 2 Type II or ISO 27001 for ZAIDYN? Where can procurement teams access these documents?
2. 21 CFR Part 11. Does ZAIDYN's platform explicitly comply with 21 CFR Part 11 for any workflows (e.g., electronic records for regulated reporting outputs)? Is there a documented compliance statement?
3. HIPAA posture. ZAIDYN processes HCP data and prescribing patterns derived from real-world data sources. What is ZS's HIPAA posture for ZAIDYN? Does ZS execute BAAs with pharma clients?
4. CRM integration depth. For each of the three listed CRM integrations (Veeva Vault CRM, Salesforce Health Cloud, IQVIA OCE): is the integration read-only (analytics overlay) or does ZAIDYN write NBA recommendations back into CRM activity records? What is the technical connector architecture?
5. NBA engine data sources. What proprietary data sets feed the ZAIDYN NBA engine beyond what clients bring? Are third-party syndicated data sources (IQVIA, Symphony Health, Komodo) licensed into the platform?
6. Named customer case studies. Amgen and Gilead are referenced in case study contexts. Are there published case studies with quantified outcomes available for procurement review?
7. ZAIDYN standalone vs. consulting-bundled. Can ZAIDYN be purchased as a standalone software license without an accompanying ZS consulting engagement? What is the minimum viable deployment scope?

Sources

ZS first-party: - https://www.zs.com/ - https://www.zs.com/about - https://www.zs.com/solutions

Third-party / analyst: - Everest Group Life Sciences AI and Analytics Services PEAK Matrix 2025 (referenced at https://www.zs.com/) - Forbes America's Best Management Consulting Firms 2025 (referenced at https://www.zs.com/)

Note on research limitations: ZS's website consistently returned 404 for deep product URLs (zs.com/solutions/*/zaidyn and related paths) as of research date. Product details were inferred from top-level page content, LinkedIn, and industry analyst references. Buyers should request a ZAIDYN product brief, compliance documentation, and reference customer list directly from ZS commercial team.